Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 61.8% in February

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 7,100 shares, a decline of 61.8% from the January 31st total of 18,600 shares. Based on an average daily trading volume, of 11,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:ARMP traded down $0.09 during midday trading on Friday, reaching $1.99. The company had a trading volume of 4,756 shares, compared to its average volume of 10,242. The company has a market capitalization of $72.00 million, a P/E ratio of -1.21 and a beta of 0.87. Armata Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.